Bennicas & Associates Inc. cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,550 shares of the company’s stock after selling 325 shares during the period. Bennicas & Associates Inc.’s holdings in Johnson & Johnson were worth $1,103,000 as of its most recent SEC filing.
Other large investors also recently modified their holdings of the company. Stuart Chaussee & Associates Inc. raised its stake in shares of Johnson & Johnson by 20.7% during the 4th quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock worth $60,000 after purchasing an additional 80 shares during the period. Selective Wealth Management bought a new stake in shares of Johnson & Johnson during the 3rd quarter worth $105,000. CKW Financial Group increased its holdings in Johnson & Johnson by 18.8% in the 4th quarter. CKW Financial Group now owns 810 shares of the company’s stock worth $105,000 after acquiring an additional 128 shares during the last quarter. Mackey Komara & Dankovich LLC purchased a new stake in Johnson & Johnson in the 4th quarter worth about $148,000. Finally, Ifrah Financial Services Inc. purchased a new stake in Johnson & Johnson in the 3rd quarter worth about $203,000. Institutional investors and hedge funds own 67.32% of the company’s stock.
Shares of JNJ opened at $137.52 on Monday. Johnson & Johnson has a fifty-two week low of $118.62 and a fifty-two week high of $148.99. The stock has a market capitalization of $368.95 billion, a P/E ratio of 16.81, a PEG ratio of 2.38 and a beta of 0.68. The company has a quick ratio of 1.20, a current ratio of 1.47 and a debt-to-equity ratio of 0.46.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 16th. The company reported $2.10 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.03 by $0.07. The business had revenue of $20.02 billion during the quarter, compared to analyst estimates of $19.55 billion. Johnson & Johnson had a return on equity of 35.79% and a net margin of 17.99%. The company’s quarterly revenue was up .1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.06 EPS. Sell-side analysts expect that Johnson & Johnson will post 8.6 earnings per share for the current year.
Several equities research analysts recently weighed in on JNJ shares. Zacks Investment Research lowered Johnson & Johnson from a “hold” rating to a “sell” rating in a report on Wednesday, January 16th. Morgan Stanley decreased their price objective on Johnson & Johnson from $153.00 to $130.00 and set an “equal weight” rating for the company in a report on Wednesday, January 2nd. Wells Fargo & Co reissued an “outperform” rating and issued a $152.00 price objective (down previously from $162.00) on shares of Johnson & Johnson in a report on Monday, January 14th. Barclays reissued an “equal weight” rating and issued a $135.00 price objective (down previously from $137.00) on shares of Johnson & Johnson in a report on Wednesday, January 23rd. Finally, Credit Suisse Group lifted their price objective on Johnson & Johnson from $151.00 to $152.00 and gave the stock an “outperform” rating in a report on Wednesday, April 17th. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $146.40.
ILLEGAL ACTIVITY NOTICE: “Johnson & Johnson (JNJ) Holdings Trimmed by Bennicas & Associates Inc.” was published by Zolmax and is owned by of Zolmax. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://zolmax.com/investing/johnson-johnson-jnj-holdings-trimmed-by-bennicas-associates-inc/3053702.html.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Recommended Story: Stop Order
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.